Author Archive | Raynovich Rod

Rayno Life Science DX and Tools Update: EXAS

Exact Sciences (EXAS) is down about 8% to $10.65 on heavy volume after a Wedbush Downgrade to Neutral. Preliminary data coming next week. The stock was added to the Rayno Life Sciences Portfolio on 12/10/10.Barron’s had a positive article on Oct 6 and the Company raised $58M in August with a follow-on offering. The stock […]

Continue Reading 0

Rayno Life Science Portfolios: Biotechnology Stocks Should Outperform in Q4

Good Day for Biotech with a Strong Appetite for Two IPOs in A Choppy Market Intercept Pharmaceuticals (ICPT) was up 29.33% to $19.40 on a public offering of 5M shares at $15 raising $75M. The Company is developing clinical stage therapeutics to treat chronic liver diseases. BofA MerrillLynch is acting as sole book running manager with […]

Continue Reading 0

Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN

Biotechnology Sector Continues Amazing Bull Run Up 40% YTD The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (BIIB) and Gilead Sciences (GILD) and with our bellwether ETF (IBB) eking out a 0.5% gain at its 52 week high. Since the bull market began in February 2009 several stocks […]

Continue Reading 0

Rayno Life Science Portfolio Dx and Tools: EXAS, ILMN,TMO

Molecular Plays Lead Rayno Dx Focus Stocks Up Illumina (ILMN) rose 4.5% today on “talk” that Roche will increase its buyout offer to $60. Roche told Bloomberg that it does not comment on rumors. Illumina was added to the Rayno Portfolio in 2/2/09 at a price of $29 and the buy was reiterated in 2012 in […]

Continue Reading 0

Who Knows About the Bull Market in Biotech Stocks?

Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip stocks”; the other from an astute investor telling a […]

Continue Reading 0

Rayno Life Science Portfolio: AMGN, EXAS, NEOG, REGN Winners on a Risk-Off Day

Biotech Stocks Remain Resilient On A Bad Day The market took a nasty turn today with a 1.36% sell-off in NASDAQ and 1.05% for the S&P. The damage was across the board but the healthcare sector rose above the flack down only 0.11%. Large cap drug and biopharmaceutical stocks were green. Our mid-cap biopharma index […]

Continue Reading 0

NASDAQ Slips Down 0.4% But Biotech Sector Hits New Highs

The ETF IBB (142.62) hit an all time high today and is up 36.6% YTD. The low for IBB over two years was August 19, 2011 at $88.50. Our mid-cap biopharma index is up 0.8% with big winners in JAZZ ($54.65) and Exelixis (EXEL $5.40) and Medivation (MDVN $106.27). Diagnostics and tools got some M&A […]

Continue Reading 0

Biotechnology Does Create Jobs and MASS Effort pays Off

The MASS Biotechnology industry has crossed $6B as a 25 year effort beginning in 1985 with the MASS Biotechnology Council. Several major biotechnology companies were created around this time such as Biogen(BIIB)  and Vertex (VRTX) as well as major venture capital firms who invested $1B in 2011 and $8B since 2002. Several major pharmaceutical firms […]

Continue Reading 0

Rayno Life Science Portfolio: ILMN, RGDX,QQQ

FED Policy Boosts Risk Assets -QQQs Should Outperform IBB We expect the biotech sector to slightly underperform NASDAQ (QQQ $70.22) in light of “QE Forever” yesterday and the shift to financials, materials, tech and other risk assets. Prior to yesterday the biotech sector has outperformed NASDAQ by as much as 15 % points so it would […]

Continue Reading 0

“QE” Forever: Buy on Rumor, Buy on News- Market Up 1.5%

Gold, financials, energy  and materials soar-Gold up $34 to $1767 You have been hearing about the FED and QE for weeks now and today announced a $40B/month purchase of mortgage securities and after a slight delay the bull market roared ahead. Interest rates will be maintained at an ultra-low rate through 2015. There was some […]

Continue Reading 0